Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy: A closed cohort study including matched control patients

Oncology

Volumn 65, Issue 3, 2003, Pages 204-210

  Ikeda, Kenji ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Someya, Takashi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Closed cohort study; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Recurrence; Sustained response

Indexed keywords

INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0345600107     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074472     Document Type: Article

References (30)

1. Bruix J, Calvet X, Costa J, et al: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;i:1004-1006.
2. Colombo M, Kuo G, Choo QL, et al: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;i:1006-1008.
3. Hasan F, Jeffers LJ, Medina MD, et al: Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591.
4. Kew MC, Houghton M, Choo QL, Kuo G: Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990;335:873-874.
5. Ikeda K, Saitoh S, Koida I, et al: A multivariate analysis of risk factors for hepatocellular carcinogenesis - A prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
6. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
7. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
8. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
9. Causse X, Godinot H, Chevallier M, et al: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101: 497-502.
10. Chayama K, Saitoh S, Arase Y, et al: Effect of interferon administration on serum hepatitis C virus RNA in patiens with chronic hepatitis C. Hepatology 1991;13:1040-1043.
11. Yoshioka K, Kakumu S, Hayashi H, et al: Anti-hepatic C antibodies in patients with chronic non-A, non-B hepatitis: Relation to disease progression and effect of interferon alpha. Am J Gastroenterol 1991;86:1495-1499.
12. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
13. Kasahara A, Hayashi N, Mochizuki K, et al: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27: 1394-1402.
14. Ikeda K, Saitoh S, Arase Y, et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
15. Shindo M, Ken A, Okuno T: Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943-1950.
16. Sugiura N, Sakai Y, Ebara M, et al: Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases. J Gastroenterol Hepatol 1996;1:35-39.
17. Tamori A, Kuroki T, Nishiguchi S, et al: Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 1996;43:1079-1083.
18. Hirashima N, Mizokami M, Orito E, et al: Case report: Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 1996;11:955-958.
19. Inoue M, Ohhira M, Ohtake T, et al: Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology 1999;46:2554-2960.
20. Miyano S, Togashi H, Shinzawa H, et al: Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 1999;14:928-930.
21. Yamaguchi K, Omagari K, Kinoshita H, et al: Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J Clin Gastroenterol 1999;29:207-209.
22. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
23. SAS Institute: SAS/STAT User's Guide, Release 6.11 Edition. Cary, SAS Institute, 1996.
24. Moreno MG, Muriel P: Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol 1995;50:515-520.
25. Tarao K, Takemiya S, Tamai S, et al: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine amino-transferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-694.
26. Dunk AA, Ikeda T, Pignatelli M, Thomas HC: Human lymphoblastoid interferon: In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986;2:419-429.
27. Lai CL, Lau JY, WU PC, et al: Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993;17:389-394.
28. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS: Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer 1988;61:2095-2099.
29. Miyagawa S, Kawasaki S, Makuuchi M: Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: Tumor multicentricity in cirrhotic liver with hepatitis B. Hepatology 1996;24:307-310.
30. Sugimoto R, Okuda K, Tanaka M, Aoyagi S, Kojiro M: Metachronous multicentric occurrence of hepatocellular carcinoma after surgical treatment - Clinicopathological comparison with recurrence due to metastasis. Oncol Rep 1999;6:1303-1308.